A FUNCTIONAL ROLE OF GAS6/TAM IN NON-ALCOHOLIC STEATOHEPATITIS PROGRESSION IMPLICATES AXL AS THERAPEUTIC TARGET.

Anna Tutusaus,Estefanía de Gregorio,Blanca Cucarull,Helena Cristóbal,Cristina Aresté,Isabel Graupera,Mar Coll,Anna Colell,Gro Gausdal,James B Lorens,Pablo García de Frutos,Albert Morales,Montserrat Marí

Cellular and Molecular Gastroenterology and Hepatology（2020）

引用 38|浏览36

暂无评分

摘要

AXL signaling, increased in NASH patients, promotes fibrosis in HSCs and inflammation in KCs, while GAS6 protects cultured hepatocytes against lipotoxicity via MERTK. Bemcentinib, by blocking AXL signaling and increasing GAS6 levels, reduces experimental NASH, revealing AXL as an effective therapeutic target for clinical practice.

查看译文

关键词

Liver Fibrosis,Hepatic Stellate Cells,Bemcentinib (BGB324),GAS6/TAM Signaling,Liver Inflammation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要